Balyasny Asset Management’s Genomic Health, Inc. GHDX Stock Holding History

Balyasny Asset Management’s Portfolio GHDX Stock Details GHDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-37,376	Closed	-$2.17M	–	1778
2019 Q2	$2.17M	Buy	37,376 +19,342	+107%	+$1.15M	0.01%	849
2019 Q1	$1.26M	Sell	18,034 -1,187	-6%	-$88K	0.01%	954
2018 Q4	$1.24M	Buy	+19,221	New	+$1.35M	0.01%	840
2017 Q4	–	Sell	-10,000	Closed	-$321K	–	2465
2017 Q3	$321K	Buy	+10,000	New	+$315K	﹤0.01%	1508
2016 Q1	–	Sell	-14,770	Closed	-$520K	–	1635
2015 Q4	$520K	Buy	+14,770	New	+$396K	﹤0.01%	821

Other funds holding GHDX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return

Balyasny Asset Management's GHDX Position: Q3 2019 in Review

Balyasny Asset Management sold out of Genomic Health, Inc. (GHDX) in Q3 2019, closing a stake of 37,376 shares — an estimated $2.17M sold.

Balyasny Asset Management first reported a position in GHDX in Q4 2015 and held it in 5 quarters. The position peaked at $2.17M in Q2 2019. 221 funds tracked by Wall St. Rank hold GHDX as of Q3 2019.

Balyasny Asset Management reported no remaining Genomic Health, Inc. position as of Q3 2019 after selling out during the quarter.
Balyasny Asset Management sold 37,376 Genomic Health, Inc. shares in Q3 2019, an estimated $2.17M.
Balyasny Asset Management first reported a position in Genomic Health, Inc. in Q4 2015 and held it in 5 quarters.
Balyasny Asset Management's Genomic Health, Inc. position peaked at $2.17M in Q2 2019.
221 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q3 2019.

Based on Balyasny Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.